<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">oncotomsk</journal-id><journal-title-group><journal-title xml:lang="ru">Сибирский онкологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Siberian journal of oncology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1814-4861</issn><issn pub-type="epub">2312-3168</issn><publisher><publisher-name>Tomsk National Research Medical Сепtеr of the Russian Academy of Sciences</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21294/1814-4861-2022-21-3-168-173</article-id><article-id custom-type="elpub" pub-id-type="custom">oncotomsk-2175</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>СЛУЧАЙ ИЗ КЛИНИЧЕСКОЙ ПРАКТИКИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CASE REPORTS</subject></subj-group></article-categories><title-group><article-title>Медуллярный рак щитовидной железы в сочетании с аутоиммунным тиреоидитом после перенесенного COVID-19</article-title><trans-title-group xml:lang="en"><trans-title>Medullary thyroid cancer in combination with autoimmune thyroiditis after COVID-19</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4045-5053</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Рябченко</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Ryabchenko</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Рябченко Евгений Викторович, кандидат медицинских наук, заведующий хирургическим отделением № 2</p><p>350012 г. Краснодар, ул. Красных партизан, 6/2</p></bio><bio xml:lang="en"><p>Evgenii V. Ryabchenko, MD, PhD, Head of the Surgical Department № 2</p><p>6/2, Krasnykh partisan str., 350012, Krasnodar</p></bio><email xlink:type="simple">rev7512@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ГБУЗ «Краевая клиническая больница № 2» Минздрава Краснодарского края, «Межтерриториальный центр эндокринной хирургии»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Krasnodar Regional Clinical Hospital № 2, Endocrine Surgery Center</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>29</day><month>06</month><year>2022</year></pub-date><volume>21</volume><issue>3</issue><fpage>168</fpage><lpage>173</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Рябченко Е.В., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Рябченко Е.В.</copyright-holder><copyright-holder xml:lang="en">Ryabchenko E.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.siboncoj.ru/jour/article/view/2175">https://www.siboncoj.ru/jour/article/view/2175</self-uri><abstract><sec><title>Актуальность</title><p>Актуальность. Коронавирусная болезнь 2019 г. (COVID-19) – пандемия нового тысячелетия. COVID-19 может вызвать как легочное, так и системное воспаление, потенциально определяя полиорганную дисфункцию. Данные о взаимосвязи между COVID-19 и щитовидной железой (ЩЖ) появляются с марта 2020 г. Щитовидная железа и вирусная инфекция, а также связанные с ней воспалительно-иммунные реакции находятся в сложном взаимодействии. Наиболее часто встречаемым аутоимунным заболеванием ЩЖ является хронический аутоиммунный тиреоидит (АИТ) (хронический лимфоцитарный тиреоидит, тиреоидит Хашимото). Медуллярный рак щитовидной железы (МРЩЖ) обнаруживают в виде узелка щитовидной железы. На момент постановки диагноза часто выявляются шейные лимфатические узлы и отдаленные метастазы. Развитие аутоантител может быть частью более сложного защитного противоопухолевого механизма, целью которого является устранение предшественников будущих опухолевых клеток.</p></sec><sec><title>Цель исследования</title><p>Цель исследования: представлен клинический случай диагностики медуллярного рака щитовидной железы после перенесенного COVID-19.</p><p>Описание клинического случая. Пациентка 43 лет, переболевшая коронавирусной пневмонией (COVID-19), на фоне которой отмечался повышенный уровень сывороточного прокальцитонина (ПК), что явилось основанием для дополнительного обследования. Из анамнеза: с 2020 г. наблюдается по поводу АИТ, который проявлялся узловым образованием щитовидной железы небольшого размера. При обследовании после выписки из COVID-стационара выполнено УЗИ ЩЖ, при котором выявлено увеличение размеров узла в левой доле до 15 мм, уровень кальцитонина – 681 пг/мл. При тонкоигольной аспирационной биопсии ЩЖ: подозрение на медуллярный рак ЩЖ. В плановом порядке выполнена тиреоидэктомия с центральной лимфаденэктомией (VI зона). При гистологическом исследовании операционного материала подтвержден медуллярный рак щитовидной железы.</p></sec><sec><title>Заключение</title><p>Заключение. В представленном клиническом случае медуллярный рак щитовидной железы выявлен после перенесенного COVID-19 с повышенным уровнем сывороточного прокальцитонина, что явилось основанием для диагностического поиска.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Background</title><p>Background. Coronavirus disease 2019 (COVID-19) is a pandemic of the new millennium. COVID-19 can cause both pulmonary and systemic infammation, and can rapidly progress to multiple organ failure. Data on the relationship between COVID-19 and the thyroid gland have been available since March 2020. The thyroid gland and viral infection as well as associated infammatory-immune reactions participate in a complex interaction. The most common autoimmune disease is chronic autoimmune thyroiditis (chronic lymphocytic thyroiditis, Hashimoto thyroiditis). The majority of medullary thyroid cancers present as a thyroid nodule. Cervical lymph nodes and distant metastases are often detected at the time of diagnosis. The development of autoantibodies may be part of a more complex protective antitumor mechanism, the purpose of which is to eliminate the precursors of future tumor cells.</p><p>The purpose of the study was to describe a clinical case of diagnosing medullary thyroid cancer in the patient who had COVID-19.</p></sec><sec><title>Case description</title><p>Case description. We present the case of a 43-year-old woman who had coronavirus pneumonia (COVID-19), which was accompanied by an increase in serum procalcitonin (PC) level, which required additional examination. Since 2020, she had been observed for autoimmune thyroiditis, which was manifested by a thyroid nodular of a small size. After discharge from the COVID hospital, an ultrasound examination of the thyroid gland revealed an increase in the left lobe thyroid nodule up to 15 mm. The level of calcitonin was 681 pg/ml. Fine needle aspiration (FNA) biopsy of the thyroid gland showed suspicion for medullary thyroid cancer. Thyroidectomy with central lymph node dissection (level VI) was performed. A planned histological examination of the surgical specimen confrmed medullary thyroid cancer.</p></sec><sec><title>Conclusion</title><p>Conclusion. In the present clinical case, medullary thyroid cancer was detected in the patient who had COVID-19 with elevated PC level, which was the basis for a diagnostic search.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>медуллярный рак щитовидной железы</kwd><kwd>кальцитонин</kwd><kwd>прокальцитонин</kwd><kwd>COVID-19</kwd><kwd>тиреоидэктомия</kwd><kwd>центральная лимфаденэктомия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>medullary thyroid cancer</kwd><kwd>calcitonin</kwd><kwd>procalcitonin</kwd><kwd>COVID-19</kwd><kwd>thyroidectomy</kwd><kwd>central lymphadenectomy</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou P., Yang X.L., Wang X.G., Hu B., Zhang L., Zhang W., Si H.R., Zhu Y., Li B., Huang C.L., Chen H.D., Chen J., Luo Y., Guo H., Jiang R.D., Liu M.Q., Chen Y., Shen X.R., Wang X., Zheng X.S., Zhao K., Chen Q.J., Deng F., Liu L.L., Yan B., Zhan F.X., Wang Y.Y., Xiao G.F., Shi Z.L. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798): 270–3. doi: 10.1038/s41586-020-2012-7.</mixed-citation><mixed-citation xml:lang="en">Zhou P., Yang X.L., Wang X.G., Hu B., Zhang L., Zhang W., Si H.R., Zhu Y., Li B., Huang C.L., Chen H.D., Chen J., Luo Y., Guo H., Jiang R.D., Liu M.Q., Chen Y., Shen X.R., Wang X., Zheng X.S., Zhao K., Chen Q.J., Deng F., Liu L.L., Yan B., Zhan F.X., Wang Y.Y., Xiao G.F., Shi Z.L. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798): 270–3. doi: 10.1038/s41586-020-2012-7.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020; 5(4): 536–44. doi: 10.1038/s41564-020-0695-z.</mixed-citation><mixed-citation xml:lang="en">Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020; 5(4): 536–44. doi: 10.1038/s41564-020-0695-z.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ahmed S., Jafri L., Hoodbhoy Z., Siddiqui I. Prognostic Value of Serum Procalcitonin in COVID-19 Patients: A Systematic Review. Indian J Crit Care Med. 2021; 25(1): 77–84. doi: 10.5005/jp-journals-10071-23706.</mixed-citation><mixed-citation xml:lang="en">Ahmed S., Jafri L., Hoodbhoy Z., Siddiqui I. Prognostic Value of Serum Procalcitonin in COVID-19 Patients: A Systematic Review. Indian J Crit Care Med. 2021; 25(1): 77–84. doi: 10.5005/jp-journals-10071-23706.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Xu J.B., Xu C., Zhang R.B., Wu M., Pan C.K., Li X.J., Wang Q., Zeng F.F., Zhu S. Associations of procalcitonin, C-reaction protein and neutrophil-to-lymphocyte ratio with mortality in hospitalized COVID-19 patients in China. Sci Rep. 2020; 10(1): 15058. doi: 10.1038/s41598- 020-72164-7.</mixed-citation><mixed-citation xml:lang="en">Xu J.B., Xu C., Zhang R.B., Wu M., Pan C.K., Li X.J., Wang Q., Zeng F.F., Zhu S. Associations of procalcitonin, C-reaction protein and neutrophil-to-lymphocyte ratio with mortality in hospitalized COVID-19 patients in China. Sci Rep. 2020; 10(1): 15058. doi: 10.1038/s41598- 020-72164-7.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Algeciras-Schimnich A., Preissner C.M., Theobald J.P., Finseth M.S., Grebe S.K. Procalcitonin: a marker for the diagnosis and follow-up of patients with medullary thyroid carcinoma. J Clin Endocrinol Metab. 2009; 94(3): 861–8. doi: 10.1210/jc.2008-1862.</mixed-citation><mixed-citation xml:lang="en">Algeciras-Schimnich A., Preissner C.M., Theobald J.P., Finseth M.S., Grebe S.K. Procalcitonin: a marker for the diagnosis and follow-up of patients with medullary thyroid carcinoma. J Clin Endocrinol Metab. 2009; 94(3): 861–8. doi: 10.1210/jc.2008-1862.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Karagiannis A.K., Girio-Fragkoulakis C., Nakouti T. Procalcitonin: A New Biomarker for Medullary Thyroid Cancer? A Systematic Review. Anticancer Res. 2016; 36(8): 3803–10.</mixed-citation><mixed-citation xml:lang="en">Karagiannis A.K., Girio-Fragkoulakis C., Nakouti T. Procalcitonin: A New Biomarker for Medullary Thyroid Cancer? A Systematic Review. Anticancer Res. 2016; 36(8): 3803–10.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Pacini F., Castagna M.G., Cipri C., Schlumberger M. Medullary thyroid carcinoma. Clin Oncol (R Coll Radiol). 2010; 22(6): 475–85. doi: 10.1016/j.clon.2010.05.002.</mixed-citation><mixed-citation xml:lang="en">Pacini F., Castagna M.G., Cipri C., Schlumberger M. Medullary thyroid carcinoma. Clin Oncol (R Coll Radiol). 2010; 22(6): 475–85. doi: 10.1016/j.clon.2010.05.002.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Meijer J.A., le Cessie S., van den Hout W.B., Kievit J., Schoones J.W., Romijn J.A., Smit J.W. Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis. Clin Endocrinol (Oxf). 2010; 72(4): 534–42. doi: 10.1111/j.1365-2265.2009.03666.x.</mixed-citation><mixed-citation xml:lang="en">Meijer J.A., le Cessie S., van den Hout W.B., Kievit J., Schoones J.W., Romijn J.A., Smit J.W. Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis. Clin Endocrinol (Oxf). 2010; 72(4): 534–42. doi: 10.1111/j.1365-2265.2009.03666.x.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Cabanillas M.E., Hu M.I., Jimenez C., Grubbs E.G., Cote G.J. Treating medullary thyroid cancer in the age of targeted therapy. Int J Endocr Oncol. 2014; 1(2): 203–16. doi: 10.2217/ije.14.26.</mixed-citation><mixed-citation xml:lang="en">Cabanillas M.E., Hu M.I., Jimenez C., Grubbs E.G., Cote G.J. Treating medullary thyroid cancer in the age of targeted therapy. Int J Endocr Oncol. 2014; 1(2): 203–16. doi: 10.2217/ije.14.26.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Gianotti L., D'Agnano S., Pettiti G., Tassone F., Giraudo G., Lauro C., Lauria G., Del Bono V., Borretta G. Persistence of Elevated Procalcitonin in a Patient with Coronavirus Disease 2019 Uncovered a Diagnosis of Medullary Thyroid Carcinoma. AACE Clin Case Rep. 2021; 7(5): 288–92. doi: 10.1016/j.aace.2021.05.001.</mixed-citation><mixed-citation xml:lang="en">Gianotti L., D'Agnano S., Pettiti G., Tassone F., Giraudo G., Lauro C., Lauria G., Del Bono V., Borretta G. Persistence of Elevated Procalcitonin in a Patient with Coronavirus Disease 2019 Uncovered a Diagnosis of Medullary Thyroid Carcinoma. AACE Clin Case Rep. 2021; 7(5): 288–92. doi: 10.1016/j.aace.2021.05.001.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Lam S.D., Bordin N., Waman V.P., Scholes H.M., Ashford P., Sen N., van Dorp L., Rauer C., Dawson N.L., Pang C.S.M., Abbasian M., Sillitoe I., Edwards S.J.L., Fraternali F., Lees J.G., Santini J.M., Orengo C.A. SARS-CoV-2 spike protein predicted to form complexes with host receptor protein orthologues from a broad range of mammals. Sci Rep. 2020; 10(1): 16471. doi: 10.1038/s41598-020-71936-5.</mixed-citation><mixed-citation xml:lang="en">Lam S.D., Bordin N., Waman V.P., Scholes H.M., Ashford P., Sen N., van Dorp L., Rauer C., Dawson N.L., Pang C.S.M., Abbasian M., Sillitoe I., Edwards S.J.L., Fraternali F., Lees J.G., Santini J.M., Orengo C.A. SARS-CoV-2 spike protein predicted to form complexes with host receptor protein orthologues from a broad range of mammals. Sci Rep. 2020; 10(1): 16471. doi: 10.1038/s41598-020-71936-5.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Han T., Kang J., Li G., Ge J., Gu J. Analysis of 2019-nCoV receptor ACE2 expression in diferent tissues and its signifcance study. Ann Transl Med. 2020; 8(17): 1077. doi: 10.21037/atm-20-4281.</mixed-citation><mixed-citation xml:lang="en">Han T., Kang J., Li G., Ge J., Gu J. Analysis of 2019-nCoV receptor ACE2 expression in diferent tissues and its signifcance study. Ann Transl Med. 2020; 8(17): 1077. doi: 10.21037/atm-20-4281.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Lazartigues E., Qadir M.M.F., Mauvais-Jarvis F. Endocrine Signifcance of SARS-CoV-2’s Reliance on ACE2. Endocrinology. 2020; 161(9). doi: 10.1210/endocr/bqaa108.</mixed-citation><mixed-citation xml:lang="en">Lazartigues E., Qadir M.M.F., Mauvais-Jarvis F. Endocrine Signifcance of SARS-CoV-2’s Reliance on ACE2. Endocrinology. 2020; 161(9). doi: 10.1210/endocr/bqaa108.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Rotondi M., Coperchini F., Ricci G., Denegri M., Croce L., Ngnitejeu S.T., Villani L., Magri F., Latrofa F., Chiovato L. Detection of SARS-COV-2 receptor ACE-2 mRNA in thyroid cells: a clue for COVID19-related subacute thyroiditis. J Endocrinol Invest. 2021; 44(5): 1085–90. doi: 10.1007/s40618-020-01436-w.</mixed-citation><mixed-citation xml:lang="en">Rotondi M., Coperchini F., Ricci G., Denegri M., Croce L., Ngnitejeu S.T., Villani L., Magri F., Latrofa F., Chiovato L. Detection of SARS-COV-2 receptor ACE-2 mRNA in thyroid cells: a clue for COVID19-related subacute thyroiditis. J Endocrinol Invest. 2021; 44(5): 1085–90. doi: 10.1007/s40618-020-01436-w.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Sigrist C.J., Bridge A., Le Mercier P. A potential role for integrins in host cell entry by SARS-CoV-2. Antiviral Res. 2020; 177. doi: 10.1016/j. antiviral.2020.104759.</mixed-citation><mixed-citation xml:lang="en">Sigrist C.J., Bridge A., Le Mercier P. A potential role for integrins in host cell entry by SARS-CoV-2. Antiviral Res. 2020; 177. doi: 10.1016/j. antiviral.2020.104759.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Davis P.J., Mousa S.A., Lin H.Y. Nongenomic Actions of Thyroid Hormone: The Integrin Component. Physiol Rev. 2021; 101(1): 319–52. doi: 10.1152/physrev.00038.2019.</mixed-citation><mixed-citation xml:lang="en">Davis P.J., Mousa S.A., Lin H.Y. Nongenomic Actions of Thyroid Hormone: The Integrin Component. Physiol Rev. 2021; 101(1): 319–52. doi: 10.1152/physrev.00038.2019.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Schmohl K.A., Mueller A.M., Dohmann M., Spellerberg R., Urnauer S., Schwenk N., Ziegler S.I., Bartenstein P., Nelson P.J., Spitzweg C. Integrin αvβ3-Mediated Efects of Thyroid Hormones on Mesenchymal Stem Cells in Tumor Angiogenesis. Thyroid. 2019; 29(12): 1843–57. doi: 10.1089/thy.2019.0413.</mixed-citation><mixed-citation xml:lang="en">Schmohl K.A., Mueller A.M., Dohmann M., Spellerberg R., Urnauer S., Schwenk N., Ziegler S.I., Bartenstein P., Nelson P.J., Spitzweg C. Integrin αvβ3-Mediated Efects of Thyroid Hormones on Mesenchymal Stem Cells in Tumor Angiogenesis. Thyroid. 2019; 29(12): 1843–57. doi: 10.1089/thy.2019.0413.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Davis P.J., Lin H.Y., Hercbergs A., Mousa S.A. Actions of L-thyroxine (T4) and Tetraiodothyroacetic Acid (Tetrac) on Gene Expression in Thyroid Cancer Cells. Genes (Basel). 2020; 11(7): 755. doi: 10.3390/genes11070755.</mixed-citation><mixed-citation xml:lang="en">Davis P.J., Lin H.Y., Hercbergs A., Mousa S.A. Actions of L-thyroxine (T4) and Tetraiodothyroacetic Acid (Tetrac) on Gene Expression in Thyroid Cancer Cells. Genes (Basel). 2020; 11(7): 755. doi: 10.3390/genes11070755.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Davis P.J., Lin H.Y., Hercbergs A., Keating K.A., Mousa S.A. Coronaviruses and Integrin αvβ3: Does Thyroid Hormone Modify the Relationship? Endocr Res. 2020; 45(3): 210–5. doi: 10.1080/07435800.2020.1767127.</mixed-citation><mixed-citation xml:lang="en">Davis P.J., Lin H.Y., Hercbergs A., Keating K.A., Mousa S.A. Coronaviruses and Integrin αvβ3: Does Thyroid Hormone Modify the Relationship? Endocr Res. 2020; 45(3): 210–5. doi: 10.1080/07435800.2020.1767127.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
